Journal
ORAL ONCOLOGY
Volume 128, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.oraloncology.2022.105847
Keywords
Cutaneous squamous cell carcinomas; Cemiplimab; Case report
Categories
Ask authors/readers for more resources
This case report presents an elderly woman with locally advanced squamous carcinoma who showed significant response and good tolerability after receiving Cemiplimab therapy. It demonstrates that immunotherapy is a new treatment option for cSCC.
Introduction: Cemiplimab, a monoclonal antibody directed against the PD-1 receptor of immune cells, has recent indication for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).Case description: We present the clinical case of an elderly woman affected by locally advanced squamous carcinoma of the left cheek, in excellent response after only one course of therapy with cemiplimab, with good tolerability.Conclusions: Immunotherapy is a new therapeutic option in cSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available